Apex BiotechnologyTPE:1733 -0.17%81 Dividend Yield % is 4.34% as of Jul. 08, 2026, which is 3% above its 10-year median of 4.23. GuruFocus rates TPE:1733 with a GF Score™ of 81/100 and a GF Value™ of NT$30.08 (Fairly Valued). The stock has 2 warning signs investors should review. Among 153 Biotechnology companies, Apex Biotechnology ranks better than 81.05% on this metric.
As of today (2026-07-08), the Trailing Annual Dividend Yield of Apex Biotechnology is 4.34%.
Good Sign:
Apex Biotechnology Corp stock Dividend Yield % is close to 2-year high.
The historical rank and industry rank for Apex Biotechnology's Dividend Yield % or its related term are showing as below:
TPE:1733'
s Dividend Yield % Range Over the Past 10 Years
Min: 0.9 Med: 4.23 Max: 10.92
Current: 4.34
During the past 13 years, the highest Dividend Yield of Apex Biotechnology was 10.92%. The lowest was 0.90%. And the median was 4.23%.
TPE:1733's Dividend Yield % is ranked better than 81.05% of 153
companies
in the Biotechnology industry
Industry Median: 1.31
vs TPE:1733: 4.34
During the past 12 months, Apex Biotechnology's average Dividends Per Share Growth Rate was 9.10% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was -2.60% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 1.40% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was -1.90% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Apex Biotechnology was 51.20% per year. The lowest was -54.10% per year. And the median was -5.10% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Apex Biotechnology Dividend Yield % Historical Data
* Premium members only.
The historical data trend for Apex Biotechnology's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TPE:1733 vs VRTX, REGN, ALNY: Dividend Yield % Comparison
For the Biotechnology subindustry, Apex Biotechnology's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apex Biotechnology Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Apex Biotechnology's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Apex Biotechnology's Dividend Yield % falls into.
Dividend Yield measures how much a company pays out in dividends each year relative to its share price.
Apex Biotechnology Recent Full-Year* Dividend History
Amount
Ex-date
Record Date
Pay Date
Type
Frequency
Forex Rate
TWD 1.300000
2026-06-09
2026-06-10
2026-07-09
Cash Dividend
annually
TWD:TWD 1.000000
* GuruFocus has an internal rule that if the most recent dividend payment frequency is at least 4 times a year, then the full year will be calculated according to the frequency of payment or the one-year time frame, whichever is stricter.
* GuruFocus converts dividend currency to local traded share price currency in order to calculate dividend yield. Please refer to the last column "Forex Rate" in the above table.
Apex Biotechnology's Trailing Annual Dividend Yield (%) for Today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apex Biotechnology (TPE:1733) has a Dividend Yield % of 4.34% as of Jul. 08, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Apex Biotechnology and its competitors. This is near median its historical median of 4.23. Over the past decade, Apex Biotechnology's Dividend Yield % has ranged from 0.90 to 10.92. According to the industry distribution chart, Apex Biotechnology ranks #29 out of 153 companies in the Biotechnology industry, placing it in the top 19%.
Is Apex Biotechnology's Dividend Yield % too high?
Apex Biotechnology's current Dividend Yield % of 4.34% is near median its 10-year median of 4.23. Over the past 10 years, this metric has ranged from a low of 0.90 to a high of 10.92. The Biotechnology industry median Dividend Yield % is 1.31. Apex Biotechnology's value of 4.34% is 231.3% above this industry median. Based on the distribution chart, Apex Biotechnology ranks #29 out of 153 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Apex Biotechnology has a GF Score™ of 81/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Apex Biotechnology's Dividend Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Apex Biotechnology ranks #29 out of 153 companies for Dividend Yield %. This places Apex Biotechnology in the top 19% of its industry — outperforming the majority of peers. The industry median Dividend Yield % is 1.31. Apex Biotechnology's value of 4.34% is 231.3% above this benchmark. Historically, Apex Biotechnology's own Dividend Yield % has ranged from 0.90 to 10.92 over the past decade. While the company's 10-year median is 4.23 vs. the industry median of 1.31, Apex Biotechnology has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.31, based on 153 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Apex Biotechnology's current Dividend Yield % of 4.34% is 231.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Apex Biotechnology and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Apex Biotechnology's current Dividend Yield % is 4.34%, which is near median its own 10-year median of 4.23. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apex Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, Apex Biotechnology (TPE:1733) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.08, compared to a current price of NT$29.90 — trading 0.6% below its estimated fair value. The current Dividend Yield % is 4.34%, which is near median its 10-year median of 4.23 and 231.3% above the Biotechnology industry median of 1.31. Apex Biotechnology's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Apex Biotechnology (TPE:1733), the current Dividend Yield % is 4.34% as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apex Biotechnology (TPE:1733) Overvalued in 2026?
Based on GuruFocus' analysis, Apex Biotechnology stock appears to be undervalued.
The current stock price of NT$29.90 is trading 0.6% below its estimated GF Value™ of NT$30.08.
GuruFocus considers Apex Biotechnology to be Fairly Valued.
Key valuation signals for TPE:1733:
Dividend Yield %: 4.34% (near median its 10-year median of 4.23)
GF Value™: NT$30.08 vs. price of NT$29.90 (0.6% below fair value)
Industry Position: 231.3% above the Biotechnology median (#29 of 153)
No single metric tells the full story. See the TPE:1733 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apex Biotechnology Corp is engaged in the research, development, production, manufacturing, and sale of biochemical testing instruments and proprietary test strips, as well as the import and export of products and components related to its core business. Its product offerings include diabetes testing kits, blood uric acid monitoring systems, blood lactate monitoring systems, blood haemoglobin monitoring systems, etc. The company generates maximum revenue from the sale of test strips, and the rest from testing meters, electrodes, and other products. Geographically, it derives maximum revenue from the USA, and the rest from Italy, Austria, Taiwan, China, and other markets.
81GF Score
Get the complete analysis for TPE:1733
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TPE:1733 has been successfully added to your 
